| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| TRBC1 | Human TRBC1 Protein, His Tag, low endotoxin (HPLC verified) | Human | HEK293 | ![]() | HPLCSDS-PAGE | $360.00 100ug | ||
| TRBC1 | Avitag TR1-H82E6 | Biotinylated Human TRBC1 Protein, His,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Invikafusp Alfa | STAR0602; STAR-0602 | Phase 2 Clinical | Marengo Therapeutics Inc | Abdominal Neoplasms; Breast Neoplasms; Carcinoma; Epstein-Barr Virus Infections; Lung Neoplasms; Neoplasms; Papillomavirus Infections; Solid tumours; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Vulvar Diseases; Vulvar Neoplasms | Details |
| TRBC1/2-Targeted CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Lymphoma, T-Cell, Peripheral | Details | |
| Anti-TRBC1 CAR-T cell therapy (Shanghai General Hospital) | Phase 1 Clinical | Shanghai General Hospital | Hematologic Neoplasms | Details | |
| FT-819 | FT-8198; FT-819; FT 8198 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Myositis; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic | Details |
